The thesis · Drug discovery from India
India's genetic diversity is the next frontier for drug discovery.
We generate clinical-grade genomic data at the point of care, across 20+ hospitals in India, and link it to clinical outcomes. The result is the population-scale, clinico-genomic resource that drug discovery has been missing.
Sequence linked to phenotype and outcome: one record that compounds in value with every patient.
clinical records, linked at the point of care
with genomic data, compounding
hospital sites across India
Why now
The diversity the world's biobanks miss, generated where care happens.
Sequencing is cheap; linked, ancestrally distinct data is not. India is where that data lives: 1.4 billion people and 4,600+ endogamous communities whose biology no European cohort can show. We generate it at the point of care, already linked to outcomes, and targets with that kind of human-genetic support are roughly twice as likely to clear the clinic.
On-demand testing
From a single panel to whole genomes at cohort scale.
Every assay you need, run on one reproducible pipeline.
Who we serve
One genomic backbone, every kind of partner.
Hospitals, prevention clinics, fertility centres, diagnostics labs, pharma and research teams, each starts from the same genomic backbone.
One company · two engines
Sequence linked to outcomes turns a cohort into a discovery engine.
Every patient we test deepens the resource: one clinical engine feeding a discovery engine, both on Health Hub, the same platform as the clinical agents.
deepens the resource.
Same standards as the clinic
HIPAA
GDPR
SOC 2 Type II
ISO 27001
FHIR R4